Ligand Pharmaceuticals (LGND) Revenue (2010 - 2026)

Ligand Pharmaceuticals has disclosed Revenue across 17 years of filings, most recently posting $51.7 million for Q1 2026.

• Revenue for Q1 2026 came in at $51.7 million, up 14.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $274.5 million (up 51.24% YoY), and the FY2025 annual result was $268.1 million, up 60.4% from the prior year.
• Revenue came in at $51.7 million for Q1 2026 at Ligand Pharmaceuticals, down from $59.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $115.5 million in Q3 2025 to a low of $26.4 million in Q2 2023.
• The 5-year median for Revenue is $45.3 million (2025), against an average of $47.9 million.
• Across the five-year window, Revenue tumbled 47.4% in 2023 and surged 122.85% in 2025, its largest moves.
• Ligand Pharmaceuticals' Revenue stood at $50.4 million in 2022, then sank by 44.22% to $28.1 million in 2023, then jumped by 52.35% to $42.8 million in 2024, then jumped by 39.37% to $59.7 million in 2025, then dropped by 13.31% to $51.7 million in 2026.
• The last three Revenue figures came in at $51.7 million (Q1 2026), $59.7 million (Q4 2025), and $115.5 million (Q3 2025), per Business Quant data.